Kyowa Kirin secures FDA approval for Crysvita dosing update
Kyowa Kirin has received FDA approval for an updated dosing regimen of Crysvita, a treatment for X-linked hypophosphatemia (XLH). The new guidelines allow healthcare providers to increase the dose and frequency for patients with low serum phosphorus levels. Crysvita, a monoclonal antibody, targets FGF23 to improve phosphorus retention and vitamin D levels. This update aims to provide a more personalized treatment approach for XLH patients, enhancing their care options.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Pharmaceutical Technology The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments